The loss of TGF-β signaling promotes prostate cancer metastasis

Neoplasia

Volumn 5, Issue 3, 2003, Pages 267-277

  Tu, William H ^a,b,c   Thomas, Tania Z ^a   Masumori, Naoya ^d   Bhowmick, Neil A ^b   Gorska, Agnieszka E ^b   Shyr, Yu ^b   Kasper, Susan ^a,b,c   Case, Tom ^a   Roberts, Richard L ^a,b   Shappell, Scott B ^a,b,c   Moses, Harold L ^b,c   Matusik, Robert J ^a,b,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Metastasis; Probasin; Prostate cancer; Transforming growth factor ; Transgenic mice

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION; TRANSGENE; TUMOR GROWTH;

EID: 10744222982     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1476-5586(03)80058-1     Document Type: Article

References (23)

1. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, and Scardino PT (1994). Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152, 1843-49.
2. Quinn DI, Henshall SM, Head DR, Golovsky D, Wilson JD, Brenner PC, Turner JJ, Delprado W, Finlayson JF, Stricker PD, Grygiel JJ, and Sutherland RL (2000). Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 60, 1585-94.
3. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, and Lee WH (1990). Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 87, 7762-66.
4. Kim IY, Ahn HJ, Lang S, Oefelein MG, Oyasu R, Kozlowski JM, and Lee C (1998). Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 4, 1625-30.
5. Guo Y, Jacobs SC, and Kyprianou N (1997). Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J Cancer 71, 573-79.
6. Morton DM and Barrack ER (1997). Modulation of transforming growth factor β1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55, 2596-602.
7. Brodin G, ten Dijke P, Funa K, Heldin CH, and Landstrom M (1999). Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Cancer Res 59, 2731-38.
8. Danielpour D (1999). Transdifferentiation of NRP-152 rat prostatic basal epithelial cells toward a luminal phenotype: regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-beta. J Cell Sci 112 (Part 2), 169-79.
9. Datta PK, Blake MC, and Moses HL (2000). Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-β-induced physical and functional interactions between Smads and Sp1. J Biol Chem 275, 40014-19.
10. Hua X, Miller ZA, Wu G, Yigong S, and Lodish HF (1999). Specificity in transforming growth factor β-induced transcription of the plasminogen activator inhibitor-1 gene: interactions of promoter DNA, transcription factor, μE3, and Smad proteins. Proc Natl Acad Sci USA 96, 13130-35.
11. Yan Y, Sheppard PC, Kasper S, Lin L, Hoare S, Kapoor A, Dodd JG, Duckworth ML, and Matusik RJ (1997). A large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Prostate 32, 129-39.
12. Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, and Matusik RJ (1998). Development, progression and androgen-dependence of prostate tumors in transgenic: a model for prostate cancer. Lab Invest 78, 319-34.
13. Masumori N, Thomas TZ, Case T, Paul M, Kasper S, Chaurand P, Caprioli RM, Tsukamoto T, Shappell SB, and Matusik RJ (2001). A probasin-large T antigen transgenic mouse line develops prostate adeno and neuroendocrine carcinoma with metastatic potential. Cancer Res 61, 2239-49.
14. Ghatak S, Oliveria P, Kaplan P, and Ho SM (1996). Expression and regulation of metallothionein mRNA levels in the prostates of noble rats: lack of expression in the ventral prostate and regulation by sex hormones in the dorsolateral prostate. Prostate 29, 91-100.
15. Serra R, Johnson M, Filvaroff EH, LaBorde J, Sheehan DM, Derynck R, and Moses HL (1997). Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J Cell Biol 139, 541-52.
16. Wang XJ, Greenhalgh DA, Bickenbach JR, Jiang A, Bundman DS, Krieg T, Derynck R, and Roop DR (1997). Expression of a dominant-negative type II transforming growth factor beta (TGF-beta) receptor in the epidermis of transgenic mice blocks TGF-beta-mediated growth inhibition. Proc Natl Acad Sci USA 94, 2386-91.
17. Matusik R, Masumori N, Thomas T, Case T, Paul M, Kasper S, and Shappell S (2001). Transgenic mouse models of prostate cancer. In Contemporary Endocrinology: Transgenics in Endocrinology. M Matzuk, C Brown, T Kumar (Eds.) Totowa, Canada Humana Press Inc, 401-25.
18. Lyon PB, See WA, Xu Y, and Cohen MB (1995). Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. Prostate 27, 179-86.
19. Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S, and Kwaan HC (1995). Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 96, 2593-600.
20. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, and Guise TA (1995). TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases. J Clin Invest 103, 197-206.
21. Derynck R, Akhurst RJ, and Balmain A (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29, 117-29.
22. Pfeilschifter J and Mundy GR (1987). Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA 84, 2024-28.
23. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd CP, Tamayo, P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff TR, Golub TR, and Sellers WR (2002). Gene expression correlates of clinical prostate cancer behavior. Cancer Cells 1, 203-209.